J&J/Cordis v. Boston Scientific
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson's Cordis unit plans to appeal a Jan. 20 ruling in Delaware federal court that found four of its drug-eluting stent patents to be invalid. The so-called Wright/Falotico patents relate to drug and polymer coatings for stents and are at issue in a 2007 suit brought by J&J/Cordis claiming infringement by Boston Scientific's Promus everolimus-eluting stent system. J&J notes that the ruling "is not expected to have any effect on Cordis' other litigation against the Promus product based on its Morris, Llanos and Fischell patent families." Last fall, Boston Scientific settled 14 other stent patent suits with J&J by paying $716 million. "We continue to attempt to resolve remaining outstanding matters with J&J," said Boston Scientific CEO Ray Elliott on Jan. 20 (1"The Gray Sheet" Oct. 5, 2009)
You may also be interested in...
Boston Scientific Settles 14 Stent Patent Suits With J&J For $716 Million
Long-time stent rivals Boston Scientific and Johnson & Johnson signed a partial patent détente Sept. 29, but the companies are not finished battling over intellectual property for the profitable devices
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.